AnserBio
PrivateLast Round
Seed
Dec 1, 2021
Total Funding Raised
$6.45M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
AnserBio is a biotechnology company developing a novel class of therapeutics for oncology treatment.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AnserBio Comparables
Compare AnserBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| p53-Therapeutics, Inc. | 78% | |
| Evox Therapeutics | 68% | |
| PMV Pharma | 66% | |
AnserBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Dec 1, 2021 |
AnserBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Israel Biotech Fund | Seed |
| Peregrine Ventures | Seed |
| ExitValley | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
Monthly visitors grew 116% MoM, reaching 1.3K.
- Dec 1, 2021
$6.45M round led by Israel Biotech Fund and Peregrine Ventures
AnserBio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AnserBio's valuation, stock price, and market status.